Related Experiment Video
Updated: Aug 29, 2025
05:26
Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications
Published on: April 13, 2022
3.5K
Potential Medical Applications of Chitooligosaccharides
1Oral Health Institute, Department of Dentistry, Hamad Medical Corporation, Qatar University, Doha 3050, Qatar.
Polymers
|September 9, 2022
Summary
Chitooligosaccharides (COS) show promise for medical applications due to their bioactivities and low toxicity. Further research is needed to explore their potential in treating various diseases.
Area of Science:
- Biochemistry
- Pharmacology
- Biomaterials
Background:
- Chitooligosaccharides (COS) are derived from chitosan, characterized by a low degree of polymerization (<20) and molecular weight (<3.9 kDa).
- COS exhibits enhanced water solubility and non-toxicity compared to chitosan, making it attractive for biomedical applications.
- A broad spectrum of bioactivities, including antibacterial, anti-inflammatory, anti-obesity, neuroprotective, anticancer, and antioxidant effects, has been reported for COS.
Purpose of the Study:
- To review recent advancements in chitooligosaccharides (COS) research.
- To explore the potential applications of COS in various diseases and conditions.
- To highlight prospects for future in vivo and translational studies of COS in medicine.
Main Methods:
- Literature review focusing on preclinical research of COS.
- Analysis of studies detailing COS production methods (enzymatic, physical, chemical).
- Synthesis of data on the bioactivities and therapeutic potential of COS.
Main Results:
- COS can be produced via enzymatic, physical, or chemical methods.
- COS demonstrates significant pharmacological potential, including antibacterial, anti-inflammatory, anti-obesity, neuroprotective, anticancer, and antioxidant properties.
- The review consolidates evidence from preclinical studies on COS efficacy.
Conclusions:
- Chitooligosaccharides (COS) possess diverse bioactivities and favorable properties for medical use.
- COS holds considerable promise for therapeutic applications across a range of diseases.
- Further translational and in vivo research is crucial to advance COS into clinical practice.
Related Concept Videos
01:24Oligosaccharide Assembly
3.0K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
3.0K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
241
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
241